Marketing agencies | Pharma Intelligence

Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

Thought leadership, Pharma Marketing Solutions

Putting Account-Based Marketing to work for your high-value clients

13 Sep 2021

Account-based marketing/engagement (ABM/ABE): this customer-centric, cross-functional approach to delivering clients and prospective clients superior marketing campaigns has become increasingly popular.

Topic Market Intelligence

Single report
Generics Bulletin

India Biosimilars Landscape

19 Aug 2021

India leads the ways with the highest number of approved biosimilars.

Topic Clinical Trials Biosimilars

View infographic
Scrip

Chinese Biotechs Join COVID-19 Treatment Race With Repurposed Cancer Drugs

By Dexter Yan 18 Aug 2021

Chinese bioventures leap into the COVID cure fray as two little-known companies kick off clinical studies of androgen receptor antagonists in Brazil and the US.

View article
Pharma Marketing Solutions, Lead generation, Pharma Brand Aw...

Benefit from the trust our subscribers have in us and reach your target audience

17 Aug 2021

As the world’s leading provider of news, analysis, and data for the pharmaceutical, generics, consumer healthcare, and medtech markets, we know your target audience – they’re our subscribers.

Topic Market Intelligence

View infographic
HBW Insight

US FDA Focused On Vulnerable Populations As Cosmetic Risk Assessment Protocol Develops

By Ryan Nelson 17 Aug 2021

The agency’s recent request for contractor quotes cites infants and children, people of color, and immunosuppressed individuals among users whose “unique biological characteristics” could require special consideration in the evaluation of cosmetic ingredients. The FDA also is interested in accounting for unique physicochemical aspects of ingredients such as engineered nanomaterials.

View article
Pink Sheet

AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis

By Sue Sutter 16 Aug 2021

After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 16 Aug 2021

In this week's podcast edition of Five Must-Know Things: a history of Alzheimer’s drug development; BioNTech looks beyond COVID-19 vaccines; gene therapy setbacks for bluebird; new promise for Roche’s Polivy in B-cell lymphoma; and rising US momentum for US drug price negotiations.

View article
HBW Insight

After US FDA Objects To CBD Safety As NDIs, Supplement Industry Responds, What Else Is New?

By Malcolm Spicer 13 Aug 2021

Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.

View article
HBW Insight

Beiersdorf Plans To Reboot Coppertone, Strengthen China Position With Anti-Dark Spot Innovations

By Lauren Nardella 12 Aug 2021

The Germany-based firm exceeded pre-pandemic sales levels in the fiscal 2021 second half, but rising costs could slow its momentum. Coppertone was a key growth driver in the second quarter, and Beiersdorf aims to capitalize with fresh innovation, new packaging and other updates to the brand.

View article
Pharma Marketing Solutions

Create award winning campaigns with Pharma Intelligence

11 Aug 2021

You need your marketing to generate better results and position your organization above the rest. You need a 3rd party who are experts in both marketing and the pharma industry and above all an organization you can trust to deliver you marketing activities. From identifying the right audiences, creating content, to executing multi-channel campaigns with engaging messaging, Pharma Intelligence can offer end to end marketing support where you need it most. Over 3,000 subscribing organizations rely on our drug, device, company, clinical trial, and market intelligence across the biopharma, medtech, generics and consumer healthcare industries, including over 80 of the top pharma, 20 of the top medtech and 35 of the top generics organizations. This video focuses on how Pharma Intelligence can help organizations raise awareness, generate leads and product thought leadership materials.

Topic Market Intelligence

Full video
Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

Topic Cancer

Single report
Scrip

Alzheimer’s Disease: Many Failures Before One Success

By Mandy Jackson 10 Aug 2021

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.

View article
Scrip

Oncology, Cell Therapy Developers Bag $175m In China

By Dexter Yan 10 Aug 2021

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 09 Aug 2021

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

View article
Scrip

Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets

By Alaric DeArment 06 Aug 2021

The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.

View article